Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women
Open Access
- 1 November 2001
- journal article
- research article
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 74 (5) , 679-686
- https://doi.org/10.1093/ajcn/74.5.679
Abstract
Background: Alterations in body composition have been reported in HIV-positive adults receiving highly active antiretroviral therapy (HAART), but the magnitude and potential determinants of these changes are unclear. Objective: We compared total and regional body composition, as measured by dual-energy X-ray absorptiometry, in 203 HIV-positive men and 62 HIV-positive women according to HAART. Design: This was a cross-sectional analysis of a cohort study of nutrition and HIV infection. Results: After adjustment for age, weight, race, and exercise habits, total weight and fat mass did not differ significantly in men or women by HAART. Trunk fat was greater in men (1.0 kg; P < 0.001) and women (1.4 kg; P = 0.005) and leg fat was lower in men (−1.0 kg; P < 0.001) and women (−1.5 kg, P = 0.005) receiving HAART than in those not. This corresponded to a greater percentage of total fat mass located in the trunk (men: 7.5%, P < 0.001; women: 5.1%, P = 0.02). Lean mass was also greater with longer duration of HAART in men (P < 0.002). In men receiving HAART, total and regional bone mineral content were less than in the men not receiving HAART (P < 0.001). These effects increased with longer duration of HAART. Protease inhibitors were associated with the largest differences in regional fat. Conclusions: HAART is associated with redistribution of fat mass from the legs to the trunk, despite no significant differences in total fat mass or weight. In men, HAART is also associated with a reduction in bone mineral content, suggesting that HAART increases the risk of central obesity and osteoporosis.Keywords
This publication has 31 references indexed in Scilit:
- Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapyAmerican Journal of Gastroenterology, 2000
- Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO* studyAIDS, 2000
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- Lipodystrophy Associated with an HIV-Protease InhibitorNew England Journal of Medicine, 1998
- Pseudo‐Cushing's Syndrome in Human Immunodeficiency Virus– Infected PatientsClinical Infectious Diseases, 1998
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998
- Abnormal fat accumulation in patients with HIV-1 infectionThe Lancet, 1998
- “Buffalo hump” in men with HIV-1 infectionThe Lancet, 1998
- Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric studyBone, 1995
- Alterations in bone turnover in HIV-positive patientsInfection, 1993